[Source: ScienceDaily] – Non-invasive imaging can measure how well patients with the most common form of breast cancer – estrogen receptor positive type – respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting the first week in June.
For more information click here.